Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $2.00 target price on the stock.

Separately, HC Wainwright increased their target price on shares of Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th.

Lineage Cell Therapeutics Stock Performance

LCTX stock opened at $0.59 on Friday. The firm has a market capitalization of $130.07 million, a price-to-earnings ratio of -4.92 and a beta of 1.16. Lineage Cell Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of LCTX. Bank of New York Mellon Corp grew its position in Lineage Cell Therapeutics by 35.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock worth $435,000 after purchasing an additional 114,762 shares during the period. Rhumbline Advisers boosted its stake in shares of Lineage Cell Therapeutics by 15.1% in the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after buying an additional 17,411 shares during the last quarter. Renaissance Technologies LLC raised its position in Lineage Cell Therapeutics by 10.0% during the second quarter. Renaissance Technologies LLC now owns 583,622 shares of the company’s stock valued at $582,000 after acquiring an additional 53,022 shares in the last quarter. XTX Topco Ltd purchased a new position in Lineage Cell Therapeutics during the second quarter valued at approximately $61,000. Finally, Raffles Associates LP boosted its position in Lineage Cell Therapeutics by 35.8% in the 2nd quarter. Raffles Associates LP now owns 4,357,781 shares of the company’s stock worth $4,346,000 after purchasing an additional 1,147,800 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.